CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval
Unusual CMS letter to Medicare Advantage plan sponsors disputes coverage exclusions of the ALS treatment on the basis of its accelerated approval status.
Unusual CMS letter to Medicare Advantage plan sponsors disputes coverage exclusions of the ALS treatment on the basis of its accelerated approval status.